TREANDA contains bendamustine hydrochloride, an alkylating drug, as the active ingredient.
TREANDA® (bendamustine hydrochloride) for Injection is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
Published Studies Related to Treanda (Bendamustine)
Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. [2011.01]
B-cell malignancies, including B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), are the most common hematologic malignancies in the western world. Although excellent response rates are achieved with standard chemoimmunotherapy, patients often relapse and additional treatment is necessary...
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. [2009.09.10]
PURPOSE: This randomized, open-label, parallel-group, multicenter study was designed to compare the efficacy and safety of bendamustine and chlorambucil in previously untreated patients with advanced (Binet stage B or C) chronic lymphocytic leukemia (CLL)... CONCLUSION: Bendamustine offers significantly greater efficacy than chlorambucil, and a manageable toxicity profile, when used as first-line therapy in patients with advanced CLL.
Phase II STUdy with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer. [2009.09]
BACKGROUND: Bendamustine is a drug with a favorable side effect spectrum and it offers a chance to overcome tumor resistance in pretreated patients with metastatic breast cancer (MBC)... CONCLUSIONS: Bendamustine can be given with a fixed flat dose, which simplifies the drug preparation. 2/5th of all treated patients responded to this therapy whereas bendamustine showed no anticancer effect in 3/5th of all patients. Bendamustine is definitely a drug with anticancer potential.
Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). [2006.04]
Purpose: This randomized phase III study compared bendamustine and prednisone (BP) to standard melphalan and prednisone (MP) treatment in previously untreated patients with multiple Myeloma (MM). Patients and Methods: To be included, patients had to have histologically and cytologically proven stage II with progressive diseases or stage III MM...
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). [2006.02]
PURPOSE: The purpose of this study was to compare the efficacy and toxicity of bendamustine, vincristine + prednisone (BOP) with a standard regimen of cyclophosphamide, vincristine + prednisone (COP) in patients with previously untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma... CONCLUSIONS: Bendamustine can efficaciously and safely replace cyclophosphamide, as used in standard COP therapy, for the treatment of patients with indolent NHL and mantle cell lymphoma. Long-term survival data suggest a clinically significant benefit for patients treated with BOP.
Clinical Trials Related to Treanda (Bendamustine)
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia [Active, not recruiting]
The objective of the first part of the study is to determine a safe dose of TRU-016 that can
be used in combination with bendamustine in patients with relapsed CLL. The objectives of
the second part of the study are to compare the safety and efficacy of TRU-016 in
combination with bendamustine to bendamustine alone in patients with relapsed CLL.
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma [Recruiting]
The purpose of the study is to determine the safety and efficacy of the use of Bendamustine
in combination with a commonly used combination chemotherapy to treat relapsed and
refractory multiple myeloma. The study will be conducted in two phases. Participants in
phase I will receive 1 of 4 escalating doses of bendamustine. Once the maximum tolerated
dose of bendamustine is determined phase II of this trial will begin. Participants in phase
II will receive the maximum tolerated dose of bendamustine in combination with standard of
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma [Active, not recruiting]
The goal of this multi-center Phase II study is to add bortezomib to the highly active
regimen of bendamustine and rituximab. In this study, bortezomib will be administered on a
weekly schedule (Days 1, 8, 15) and will be added to bendamustine/rituximab given in 4-week
cycles. This combination uses the standard bendamustine dosing schedule, and is more
convenient than the 5-week regimen of these 3 drugs currently being studied.
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) [Terminated]
This phase I trial is studying the side effects and best dose of alemtuzumab when given
together with bendamustine hydrochloride in treating patients with relapsed chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that did not respond to
fludarabine phosphate. Drugs used in chemotherapy, such as bendamustine hydrochloride, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as alemtuzumab, can also block
cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
Others find cancer cells and help kill them or carry cancer-killing substances to them.
Giving bendamustine hydrochloride together with alemtuzumab may kill more cancer cells.
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) [Recruiting]
This is a phase 1/2 multicenter study to assess the safety and effectiveness of brentuximab
vedotin and bendamustine, when given together, in patients with Hodgkin Lymphoma or
Anaplastic Large Cell Lymphoma (ALCL) that has either returned or did not respond to initial
treatment(s). Patients will be accrued at Columbia University Medical Center (CUMC) and at
two subsites in Canada.
Reports of Suspected Treanda (Bendamustine) Side Effects
White Blood Cell Count Decreased (38),
Platelet Count Decreased (33),
Neutrophil Count Decreased (32),
Fatigue (28), more >>
Page last updated: 2011-12-09